ADI-001 not checked

Adicet Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
Main trialPhase 1
“ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up”In the company’s words, NCT06375993 on ClinicalTrials.gov

Other drugs for Lupus Nephritis

All 45 drugs for Lupus Nephritis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Enrolling by invitation Dec 2026 A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
Phase 1Recruiting 30 Mar 2027 A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
Phase 1Terminated 3 Feb 2025 A Phase 1 Study of ADI-001 in B Cell Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ADI-001

Following is part of Solo: you see every change to ADI-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in